On this page
What the dated primary record establishes
GSK’s February 2022 filed announcement described Gilead paying ViiV Healthcare US$1.25 billion upfront and a 3% royalty on specified U.S. sales. It described distribution by ViiV’s ordinary shareholdings after Shionogi contingent consideration and applicable tax. GSK’s stated ordinary shareholding was 78.3%.
The 2022 financial note later reports that ViiV received the upfront payment on 15 February 2022. A received upfront payment does not establish future royalties or GSK’s final net cash. The worldwide patent-licence description and the U.S. royalty base are separate scopes.
Test the decision in your own operation
For your licensing or jointly owned U.S. business, draw the money route through the legal entities. The customer’s payment, the recipient’s earnings and the parent’s distribution are three different records. Use this original ELN bridge with the actual agreements.
| Record to establish | Evidence to bring | Owner decision |
|---|---|---|
| Paying customer and base | Named payer, covered products, geography, rate and period | Which transaction actually earns the fee? |
| Receiving entity | Contractual recipient, bank receipt and its own obligations | What belongs to that company before owners receive anything? |
| Prior deductions | Supported contingent payments, taxes and other applicable adjustments | Which amounts come before the shareholder allocation? |
| Owner distribution | Actual economic rights, approvals, currency and payment date | What can this parent receive, and when? |
Resolve the next commitment
Fictional example: assume a jointly owned recipient has US$100,000 available before an agreed US$20,000 prior deduction, with the remaining US$80,000 distributable 60/40. The 60% owner’s amount is US$48,000. Applying 60% to the original US$100,000 would overstate that amount by US$12,000. These invented terms are not ViiV’s calculation or tax treatment.
Use Relationship factsheet to record the payer, recipient, shareholders and payment responsibilities. Keep the detailed distribution calculation and dated cash schedule with the actual agreements. A headline royalty rate cannot replace that entity-by-entity work.
Scope
- The historical announcement and financial note do not disclose the entire settlement, current royalty receipts, net parent distributions or another company’s tax treatment.
- The fictional allocation assumes the deduction precedes distribution; actual preference rights, liabilities and distribution restrictions can change the result.
Next step
A recipient-to-parent cash bridge identifying equity rights, deductions, distribution approval and currencies without assuming gross royalty equals owner cash. Identify the entity receiving the fee, prior obligations and the actual rights governing each owner’s payment.
Terms used here
- Royalty base
- The sales or other defined measure to which an agreed royalty rate applies; it is not automatically every product or worldwide sale.
- Contingent consideration
- An additional payment obligation whose amount depends on specified future events or performance; its contract and accounting treatment need separate reading.
Sources & review notes
GSK, filed with the U.S. SEC
Passage, dates and research notes
company-regulatory-filing · Complete filed announcement; Financial Considerations and shareholder/CCL notes, plus cautionary statement
The announcement describes expected payments and the recipient’s shareholder arrangements. Ordinary share percentages are not assumed to equal every earnings right or gross cash distribution.
GSK, SEC-filed financial note 7
Passage, dates and research notes
company-regulatory-filing · Note 7 footnote 2, actual 15 February 2022 receipt and defined US royalty scope/period
The note reports the upfront payment actually received, separately from future royalty terms and unrelated operating items. The SEC filing date was checked against the retained official index.
Bookmark this guide or mark it as read.
Progress privacy
Saving is off by default. Without it, progress lasts only on this page. If you turn it on, this browser profile stores public content IDs and the progress you record. Anyone sharing the profile could see them. No plan inputs or contact details are included. Reset or export in learning settings.
This is a reading aid, not evidence of disclosure delivery, expertise or legal approval.